The cyclin-dependent kinase (Cdk) inhibitor p27 regulates cell proliferation, cell motility and apoptosis, and is inactivated through various means in many types of human cancer.
CDKN1B - Cyclin-Dependent Kinase Inhibitor 1B / p27
Abbreviation: CDKN1B, p27, p27Kip1
Type: Cyclin-dependent kinase inhibitor / cell-cycle regulator
Function: CDKN1B/p27 inhibits cyclin-CDK complexes, particularly cyclin E-CDK2 and cyclin A-CDK2, thereby restricting G1/S cell-cycle progression. It also regulates differentiation, transcription, cytoskeletal organization, cell migration, and cellular responses to growth-factor signaling.
Cancer: ↕ Context-dependent, but predominantly tumor-suppressive. Reduced nuclear p27 expression or functional loss can promote uncontrolled proliferation, tumor progression, and treatment resistance. However, cytoplasmic p27 can acquire CDK-independent pro-oncogenic functions that promote cell motility, invasion, and aggressive tumor behavior.
|